Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Orion

PlayORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses

ORION-1: inclisiran shows sustained LDL cholesterol lowering with 2 doses

ESC 2017: Further data from the ORION-1 trial, first reported earlier this year, showed a sustained and durable LDL cholesterol lowering response extending to Day 360 after one or two doses (1,2). Inclisiran is a novel siRNA inhibitor to PCSK9 which specifically targets intracellular PCSK9…

read more »
PlayProf Kausik Ray: Inclisiran, new kid on the block, looks good in ORION

Prof Kausik Ray: Inclisiran, new kid on the block, looks good in ORION

Watch out PCSK9 monoclonal antibodies: inclisiran (formerly known as PCSK9si and ALN-PCSsc) has made its mark at ACC.2017. Results of the phase 2 ORION-1 trial in patients with elevated LDL cholesterol despite maximally tolerated statin therapy, showed that 2 single injections of inclisiran 300 mg…

read more »
PlayAnthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016

Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016

Anthony Wierzbicki, Guy’s & St Thomas’ Hospitals, London discusses the implications of key trials at AHA 2016 GLAGOV ORION

read more »
ORION I: Durability of response with PCSK9 RNA interference agent

ORION I: Durability of response with PCSK9 RNA interference agent

The first in class PCSK9 RNA interference agent, inclisiran (previously known as ALN-PCSsc) showed sustained lowering of low-density lipoprotein cholesterol (LDL-C) on top of the standard of care including statins, according to early results from the ORION-1 study. Until recently, the main focus of therapeutic…

read more »